Background--High-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation, may promote atherosclerosis, particularly among adults with elevated blood pressure; however, data are sparse. We examined the association between hsCRP concentrations and risk of total stroke by hypertension status (normotension, prehypertension, and hypertension) among men in the Physicians' Health Study (PHS).
levated blood pressure (BP) is a powerful risk factor for both ischemic and hemorrhagic stroke. 1, 2 Stroke risk increases monotonically across the range of systolic BP (SBP), with an 8% increase in risk of stroke for each 10-mm Hg increase in SBP among white adults and a 24% greater risk among black adults. 3 Hypertension (SBP ≥140 mm Hg and/ or diastolic BP [DBP] ≥90 mm Hg) is the most common major modifiable risk factors for stroke in the United States, with a prevalence of nearly 30% among adults. 4 In addition, the prevalence of prehypertension among US adults is 36% (SBP 120 to <140 mm Hg, DBP 80 to <90 mm Hg, no current or past history of antihypertensive medication use) and has been consistently associated with greater risk of total incident and fatal stroke. Stroke risk has been shown to increase with the severity of prehypertensive status 5 and is intermediate among the associations observed for optimal BP and hypertensive status. 6 Prehypertension and hypertension status cluster with stroke risk factors, such as high-sensitivity C-reactive protein (hsCRP), elevated body mass index, and glucose. 7 C-reactive protein (CRP), a marker of low-grade systemic inflammation, has been associated with greater risk and severity of total and ischemic stroke in healthy populations. 8, 9 Among 22 676 Japanese men and women, hsCRP above the median was associated with >2-fold increased risk of ischemic stroke among prehypertensive participants and >3-fold risk among hypertensive participants compared with those with optimal BP. 9 Elevated hsCRP concentrations have also been associated with endothelial dysfunction, differentiation of macrophages, and smooth muscle cell proliferation. 10 Moreover, elevated inflammation among prehypertensive and hypertensive adults may exacerbate and accelerate the atherogenic process. Hence, to understand the relationship between inflammation and stroke among persons with elevated BP, we examined the association between hsCRP concentrations and stroke by hypertension status in a large prospective cohort.
Materials and Methods

Physicians' Health Study
We used data from the follow-up cohorts of the Physicians' Health Study (PHS) I 11, 12 and PHS II randomized trials. 
High-Sensitivity C-Reactive Protein Assay
Participants were asked to have their blood drawn into provided Vacutainer tubes (Becton Dickinson), centrifuged, and returned on cold packs by prepaid overnight courier. On receipt, samples were immediately aliquoted and stored at À80°C in liquid nitrogen freezers. The hsCRP levels (in mg/L) were measured by enzyme-linked immunosorbent assay based on purified protein and polyclonal antibodies (Calibiochem) and standardized to the World Health Organization First International Reference Standard.
14 As reported previously, the assay had sensitivity of 0.08 lg/mL with a mean intra-assay coefficient of variation of 4.2%. CRP has also been shown to remain relatively stable over 5 years (age-adjusted correlation coefficient 0.6, P=0.001). 15 Total and high-density lipoprotein cholesterol was measured using standard laboratory assays, as described previously. 14 
Stroke Assessment
All incident nonfatal and fatal strokes diagnosed after blood draw through the end of follow-up in 2012 were included in these analyses. Men (or next of kin for decedents) reporting stroke on follow-up questionnaires were asked for permission to review medical records. Deaths were detected through information provided by the next of kin and postal authorities and were verified by medical records and death certificates. Follow-up of morbidity and mortality in the PHS is >99% complete. Documentation of stroke events required evidence of a cerebrovascular event obtained from all available sources, including death certificates (for fatal events) and hospital records. Stroke was classified according to criteria established by the National Survey of Stroke 16 requiring evidence of a focal neurological deficit with sudden or rapid onset that persisted for >24 hours or until death. Strokes were classified as ischemic, hemorrhagic (including subarachnoid and intraparenchymal hemorrhage), and stroke of unknown subtype. We counted only stroke diagnoses that were confirmed after review of all medical records and reports of brain imaging by an end points committee of physicians, with excellent interobserver agreement. 17 Interrater reliability was also high for ischemic stroke (96.4%, j=0.84) and hemorrhagic stroke (97.1%, j=0.87). 17 The primary end points for this study were total stroke (ischemic, hemorrhagic, and strokes of unknown subtype), with ischemic and hemorrhagic stroke as secondary end points.
Statistical Analysis
Distributions of baseline characteristics were compared by clinical categories of hsCRP. 18 Partial Spearman correlation coefficients for hsCRP and cardiovascular risk factors were adjusted for age. Multivariable Cox models estimated the association between hsCRP and risk of total stroke presented by hazard ratios (HRs) and corresponding 95% CIs. In addition, hsCRP was modeled as continuous after log transformation, according to clinically defined categories (<1, 1 to ≤3, >3 mg/L), and dichotomized at >3 mg/L. Furthermore, we considered the 95th percentile of hsCRP as an upper threshold (<1, 1 to ≤3, >3 to <5.6, ≥5.6). Linear trend was assessed by modeling the median value of each category as ordinal. Self-reported hypertension status, cardiovascular and lifestyle factors, and alcohol consumption were obtained from the last questionnaire for those not randomized into PHS II or from the baseline questionnaire prior to randomization in PHS II. Hypertension status was defined as normotension (SBP <120 and DBP <80 and no current or past history of treatment for hypertension), prehypertension (SBP 120 to <140 mm Hg or DBP 80 to <90 mm Hg and no current or past history of antihypertensive medication use), or hypertension (SBP ≥140 mm Hg and/or DBP ≥90 mm Hg or current or past history of antihypertensive medication use). Self-reports of BP among a similar population of male health professionals demonstrated high agreement between reported and confirmed hypertension status. 19 Self-reported physical activity, diet, hormonal status, and chronic disease outcomes (hypertension, diabetes, and heart disease) have been validated previously in similar populations. [20] [21] [22] [23] We considered 3 multivariable models. Model 1 adjusted for potential confounders (age, smoking status, physical activity, aspirin use, and PHS cohort). Model 2 (primary model) further adjusted for chronic disease factors associated with stroke risk (body mass index; antihypertensive medication; cholesterol medication; history of hypertension, atrial fibrillation, and diabetes). Model 3 further adjusted for markers of stroke risk (SBP, DBP, total and high-density lipoprotein cholesterol). Indicator variables were assigned for missing values of physical activity (n=36, <1%), antihypertensive medication (n=97, <1%), alcohol (n=47, <1%), and cholesterol medication (n=270 <3%). The HR (95% CI) of total, ischemic, and hemorrhagic stroke by prehypertension and hypertension status was calculated. Effect modification of hsCRP (≤3 or >3 mg/L) and total stroke was evaluated by selected stroke risk factors (age, hypertension status, SBP, DBP, use of hypertension medication, cholesterol medication, body mass index, history of diabetes, atrial fibrillation, and smoking status). The likelihood ratio test comparing a multivariable model adjusted for main effects to a model including interaction terms was used to test for significant interactions. All P values were 2-sided. Analyses were conducted with SAS (version 9.2; SAS Institute).
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Results
All baseline risk factors varied significantly across categories of hsCRP (P<0.05) except for aspirin use and alcohol consumption (Table 1) . Men with elevated hsCRP (>3 mg/L) were significantly more likely to be older, current users of antihypertensive medication and/or cholesterol medication, and current smokers and to have a history of diabetes and atrial fibrillation. We observed moderately strong, significant, positive, age-adjusted Spearman correlations (P<0.001) for hsCRP and body mass index (r=0.32) and modest, significant, positive correlations with SBP (r=0.12), DBP (r=0.09), and total cholesterol (r=0.04). Modest, significant, negative correlations (P<0.001) were observed with high-density lipoprotein (r=À0.22) and alcohol (r=À0.05).
Over 15 years of follow-up (median 11.8 years, interquartile range 10.8 to 13.3 years), there were 395 confirmed total stroke events (338 ischemic, 56 hemorrhagic, and 1 unknown). There were 21 total strokes among normotensive men (12 per 10 000 person-years), 110 among prehypertensive men (22 per 10 000 person-years), and 264 among those with hypertension (52 per 10 000 person-years). In multivariable analyses, men with elevated hsCRP (>3 mg/L) had significantly greater risk of total stroke compared with those with low hsCRP concentrations (<1 mg/L; P trend =0.01) ( Table 2 , model 2), and risk associated with hsCRP exhibited monotonic log-linear association (HR 1.18, 95% CI 1.07 to 1.29). Estimates were only slightly attenuated and remained statistically significant after adjusting for BP and biomarkers of stroke risk. When we considered a value of hsCRP ≥95th percentile (≥5.6 mg/L), results were materially unchanged (data not shown).
Elevated hsCRP (>3 mg/L) among hypertensive men was associated with a significantly greater risk of total stroke, similar to the association in the population overall. Among prehypertensive men, hsCRP >3 mg/L was associated with an elevated but nonsignificant increased risk of total stroke. Estimates for normotensive men were unstable due to few events (n=21), of which only 4 events were among those with hsCRP ≥1 mg/L. Findings were unaltered after restriction to hsCRP concentrations <10 mg/L.
When ischemic and hemorrhagic stroke were examined separately (Table 3) , hsCRP >3 mg/L was associated with significantly greater risk of ischemic stroke; estimates for hemorrhagic stroke were elevated but not statistically significant due to a limited number of incident events (n=56). Among hypertensive men, hsCRP >3 mg/L was associated with a significantly greater risk of ischemic stroke compared with hsCRP <1 mg/L. Among normotensive and prehypertensive men, elevated hsCRP was not significantly associated with risk of ischemic stroke.
There was no evidence to suggest that the association between hsCRP and total stroke varied significantly by any a priori stroke risk factors (Table 4 ) (P interaction >0.05).
Discussion
In this population of >10 000 men free of known cardiovascular disease at baseline, elevated hsCRP (>3 mg/L) was associated with a significantly greater risk of total stroke compared with low hsCRP (<1 mg/L). This association did not significantly differ by hypertension status or other stroke risk factors; however, only 21 stroke events were observed among normotensive participants, underscoring the role of elevated BP in stroke risk. Furthermore, men with elevated hsCRP (>3 mg/dL) exhibited a similarly increased risk of both ischemic and hemorrhagic stroke.
We are aware of only 2 studies that have examined hsCRP and the risk of developing stroke by hypertensive status, with only 1 specifically examining prehypertensive participants.
Among a population of middle-aged Japanese adults, 9 in analyses that directly compared CRP across hypertension status, prehypertension status was associated with a nonsignificantly elevated risk of ischemic stroke (HR 1.72, 95% CI 0.93 to 3.18) compared with normotension. Moreover, prehypertensives with elevated CRP and hypertensives with low CRP (population median: men ≥0.5 mg/L, women ≥0.4 mg/L) exhibited a similarly increased risk of ischemic stroke compared with normotensive participants with low CRP stroke pathophysiology. 25 Moreover, elevated CRP concentrations may exacerbate the underlying proatherothrombotic environment of hypertension. 26 CRP has been independently associated with increases in BP 27 and incident hypertension, [28] [29] [30] although these associations may be confined to older populations. 31 Whether CRP plays a causal role or Data for models are shown as hazard ratio (95% CI). Models 1 to 3 are described in Table 2 . Model 2a: Adjusted for covariates in Model 2 excluding history of atrial fibrillation, diabetes, and hypertension medication, due to model stability. Model 3a: Model 2a plus systolic blood pressure, diastolic blood pressure, total cholesterol, and high-density lipoprotein cholesterol. P=0.45 for interaction between CRP and ischemic stroke by hypertension status. P=0.47 for interaction between CRP and hemorrhagic stroke by hypertension status. CRP indicates C-reactive protein.
*Stratum-specific estimates for normotensive not included due to limited number of events either overall or in exposed categories (ischemic stroke: 4 events for CRP ≥1; hemorrhagic stroke: 2 events total).
serves as a marker of subclinical disease remains under debate. 26 Our data indicate that CRP does not influence risk of stroke through hypertension and is not modified by hypertension status, suggesting an independent role for CRP in stroke risk, potentially through other pathways. It is unclear whether CRP significantly improves long-term prediction of stroke. Current guidelines do not support CRP measurement for stroke risk assessment in healthy or highrisk populations 24 ; however, our data suggest that elevated CRP concentrations (>3 mg/L), regardless of hypertension status, were associated with greater risk of total stroke. Persons with prehypertension and elevated CRP may represent an intermediate-risk group that might be targeted for early intervention or clinical trials. 1 Given the high prevalence of prehypertension and hypertension in the United States, with higher estimates among men and particular racial/ethnic minorities, 32 even modest elevations of risk in this group may have a substantial public health impact. We were unable to examine ischemic stroke subtypes for which atherosclerotic mechanisms may play a more prominent role. These analyses used a single baseline measurement of hsCRP, which may be subsequently influenced by subclinical disease and medication use, particularly statins, for which use increased considerably during follow-up. In analyses excluding those on cholesterol medication at baseline, however, the association between elevated hsCRP (>3 mg/L) and total stroke was materially unchanged compared with the full cohort analysis (Table 4) . Furthermore, previous work by our group has demonstrated long-term stability of hsCRP. 15, 24 BP was collected by self-report rather than direct measurement, and that may bias results toward the null; however, these self-reported measures have shown high validity and reliability in this and similar populations of physicians. 19, 33 In addition, analyses examining variation by key stroke risk factors may have been underpowered and warrant further study. Notable strengths of this study include %15 years of followup with hsCRP concentrations collected prior to stroke events and a comprehensive collection of potential confounders in a socioeconomically homogenous population. Furthermore, in contrast to previous studies, 8 our data suggested a strong positive association between CRP and hemorrhagic stroke despite the smaller number of incident hemorrhagic events, of which the majority were intraparenchymal (n=40) rather than subarachnoid hemorrhage (n=6).
Summary
In this cohort of middle-aged and older men free of baseline cardiovascular disease, we found a positive association between hsCRP concentrations and risk of total stroke. The association was not significantly different between prehypertensive and hypertensive men compared with normotensive men. Elevated hsCRP (>3 mg/L) demonstrated a strong positive association with risk of hemorrhagic stroke; however, estimates were not statistically significant. Our data suggest that evaluating CRP concentrations among these high-risk groups may provide a useful tool to identify populations requiring more intensive risk factor reduction and stroke education.
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